Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

143.90 -3.01 (-2.05%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,384,275
Open 145.56
Bid (Size) 143.90 (1)
Ask (Size) 143.94 (3)
Prev. Close 146.91
Today's Range 142.79 - 145.62
52wk Range 75.56 - 148.15
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk Halts Late-Stage Study Of Experimental Hypertension Drug, Takes Over $800M Impairment Charge
Novo Nordisk announced the failure of its phase 3 CLARION-CKD trial, which investigated ocedurenone for treating uncontrolled hypertension in advanced chronic kidney disease patients. The trial did not... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
+40.93%
+40.93%
1 Month
+7.32%
+7.32%
3 Month
+11.20%
+11.20%
6 Month
+40.14%
+40.14%
1 Year
+83.06%
+83.06%

More News

Read More
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
Via InvestorPlace
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Via The Motley Fool
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
A Closer Look at Novo Nordisk's Options Market Dynamics
Via Benzinga
Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
Via Benzinga
Why Novo Nordisk Shares Are Trading Higher Tuesday
Via Benzinga
Novo Nordisk Wins Approval For Its Weight-Loss Drug From China
Via Talk Markets
European Stocks Dip As US Market Sentiment Sours
Via Talk Markets
Why Is Regis (RGS) Stock Up 215% Today?
Via InvestorPlace
Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock
Via InvestorPlace
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
Via The Motley Fool
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
Via InvestorPlace
Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China
Via Benzinga
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Via Investor's Business Daily
Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs
Via Benzinga
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Via Benzinga
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Via Benzinga
Exposures Product Safety
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
Via InvestorPlace
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
Via InvestorPlace
Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
Via Benzinga
3 Biotech Stocks to Buy Now: June 2024
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.